MedTrace Logo

Human CNS Tau Kinetics in Tauopathies

NCT03545126 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2022-04-13

No results posted yet for this study

Summary

The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.

Conditions

  • Progressive Supranuclear Palsy (PSP)
  • Corticobasal Degeneration (CBD)
  • Frontotemporal Dementia (FTD MAPT Mutation)

Interventions

OTHER

13C6 Leucine

Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)

Sponsors & Collaborators

  • Association of Frontotemporal Degeneration

    collaborator UNKNOWN

  • Tau Consortium

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Randall Bateman, MD · Washington University in Saint Louis Medical School

  • Nupur Ghoshal, MD, PhD · Washington University in Saint Louis Medical School

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-21
Primary Completion
2022-03-04
Completion
2022-03-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545126 on ClinicalTrials.gov